D2 Novel Imaging and Theranostics

Theme lead:

The group will leverage its current expertise and infrastructure in real-time chemical imaging and microscopy towards a better understanding of molecular and cellular processes of development and growth of cancer at multiple stages. To this extent the group endeavours in developing tools, techniques, and methodologies for imaging with greatly increased speed, penetration, spatial and temporal resolution, sensitivity, specificity and depth of focus. Real-time data handling, image processing, and automatic decision making is another cornerstone of imaging for cancer diagnosis and therapy. Our activity will involve imaging cancer screening, discovery, diagnosis, and treatment.in both research and clinical settings. As such, it will include clinical imaging in radiology, pathology, endoscopy, and nuclear medicine, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, and nanomedicine for theranostics, new techniques and applications of image processing, pattern recognition and automatic decision making towards personalized screening, diagnosis, therapy, monitoring and follow up. We will bring new and robust solutions to improve the standardization of quantitative imaging and image-guided interventions for the diagnosis and treatment of cancer.  The five key objectives of our activities are:

• Molecular and Cellular Imaging to understand the disease process, early diagnosis, effective intervention
• Nanomedicine for Fast, Better Contrast Cancer Imaging and Combinatorial Therapy
• Image Processing, Classification, Phenotyping
• Automatic Decision-Making, Early Intervention, and Drive Towards Zero Recurrence
• Clinical Convergence, Translation, (Re)training, Commercialisation